Harmony Biosciences Holdings, Inc. (HRMY) - Q2 2026 Filing Summary
Business Context and Reporting Period
This summary covers the unaudited quarterly report (Form 10-Q) for Harmony Biosciences Holdings, Inc. for the period ended June 30, 2026. Harmony is a neuroscience company focused on rare neurological diseases, primarily commercializing WAKIX® (pitolisant) for narcolepsy. The company operates in a single reportable segment and is headquartered in Plymouth Meeting, Pennsylvania.
Key Financial Metrics (Six Months Ended June 30, 2026)
| Metric | Value (in thousands) |
|---|---|
| Net Product Revenue | $476,667 |
| Gross Profit | $368,957 |
| Operating Income | $126,607 |
| Net Income | $107,919 |
| Diluted EPS | $1.84 |
| Cash, Cash Equivalents, and Investments | $962,459 |
| Total Debt (Principal) | $155,000 |
| Operating Cash Flow | $120,192 |
Material Changes vs. Prior Period
- Revenue Growth: Net product revenue increased by 23.7% ($91.4 million) compared to the six months ended June 30, 2025. This was driven by a 19.4% increase in units shipped and a 7% price increase implemented in January 2026, partially offset by higher rebates.
- Profitability: Net income rose 26.5% to $107.9 million from $85.3 million in the prior year period. Operating income increased to $126.6 million from $104.4 million.
- Cost Structure: Cost of product sold increased 53.5% to $107.7 million, primarily due to higher royalties tied to revenue growth and new royalties from the Novitium License Agreement. Gross margin decreased slightly to 77.4% from 81.8%.
- R&D Expenses: Research and development expenses increased 36.9% to $116.0 million. This increase was driven by $32.0 million in acquired in-process research and development (IPR&D) charges related to new license agreements (Novitium and MSN) and increased clinical trial costs for BP-205, EPX-100, and Pitolisant GR/HD.
- Investing Activities: Net cash used in investing activities surged to $315.1 million (from $17.2 million prior year) due to $331.5 million in purchases of investment securities and $32.0 million in upfront license fees.
Guidance, Outlook, and Risks
- Pipeline Progress:
- Pitolisant GR: NDA submitted to FDA in June 2026; target PDUFA date is April 1, 2027.
- BP-205: IND submitted to FDA in July 2026; Phase 1b study initiation expected in Q3 2026.
- EPX-100: Phase 3 trials ongoing for Dravet and Lennox-Gastaut syndromes; topline data expected in 2027.
- Commercial Outlook: Management expects continued growth in WAKIX sales, supported by formulary access for over 80% of insured lives. Average patients on WAKIX reached approximately 8,950 in Q2 2026.
- Liquidity: The company holds $962.5 million in cash and investments, sufficient to fund operations for at least the next 12 months.
- Legal & Contingencies:
- ANDA Litigation: Harmony has settled disputes with multiple generic applicants (Lupin, Novugen, Novitium, Hikma, Annora, MSN). Settlements generally allow generic entry in July 2030 (contingent on pediatric exclusivity) or March 2030.
- Patent Litigation: A new lawsuit was filed in April 2026 against AET and Sandoz regarding patent infringement (U.S. Patent No. 11,623,920).
- Debt Covenant: A nonfinancial covenant default regarding a subsidiary guarantor (dating to July 2025) was waived on May 4, 2026. The company is currently in compliance.
Investor Verification Checklist
- Verify the impact of the July 2030/March 2030 generic entry dates on long-term revenue projections for WAKIX.
- Monitor the IPR&D charges ($32 million in H1 2026) and their effect on near-term earnings versus long-term pipeline value.
- Confirm the status of the ANDA litigation against AET/Sandoz filed in April 2026 and potential settlement terms.
- Review the royalty structure under the new Novitium and MSN agreements and its impact on gross margins as revenue scales.
- Assess the cash burn rate relative to the $962 million cash balance given the heavy investment in clinical trials and new licenses.